The research, conducted by Sergej L. Mironov of the Institute of Neuro- and Sensory Physiology at Georg-August-University in Göttingen, Germany, introduces a novel analytical framework for solving reaction-diffusion equations by applying the Wentzel-Kramers-Brillouin-Jeffreys (WKBJ) formalism to calcium buffering. The WKBJ method, familiar to physicists as a semiclassical approximation used to solve the stationary Schrödinger equation in quantum mechanics, has rarely been applied to time-dependent reaction-diffusion systems. Mironov’s work demonstrates that this mathematical machinery, borrowed from quantum mechanics, can yield compact closed-form solutions for the spatiotemporal distributions of free calcium and calcium-bound buffer species in one, two, and three dimensions.

The theoretical foundation builds upon the Michaelis-Menten equation, which has served for more than a century as the fundamental tool for describing biochemical reactions. However, classical formulations generally describe either spatially homogeneous systems or highly localized reactions in which diffusion is neglected. Wagner and Keizer incorporated Michaelis-Menten kinetics, also known as the rapid buffer approximation, into a reaction-diffusion framework in 1994, deriving a nonlinear equation for total calcium concentration that they analyzed numerically. Mironov’s new work extends this lineage by explicitly incorporating diffusion into Michaelis-Menten-type kinetics and deriving analytical solutions using the Liouville-Green transformation, commonly known in quantum mechanics as the WKBJ approximation.

The key theoretical prediction is remarkable: a sustained calcium source produces continuously expanding distributions of free calcium, whereas the concentration of calcium-bound buffers develops on a much slower timescale but propagates as traveling fronts that move away from the source. The calculations reveal that these bound-species waves travel at velocities of roughly 300 to 400 micrometers per second under default parameters, largely independent of spatial dimensionality. Buffer mobility emerges as a major determinant of intracellular calcium patterns. When buffer diffusion coefficients approach that of free calcium, both free and bound distributions remain spatially confined, supporting the classical nanodomain concept. But when buffers are slow or effectively immobile, as is the case for many endogenous cytoplasmic calcium-binding proteins, calcium-bound molecules progressively spread throughout the cytoplasm rather than remaining localized.

These predictions were tested experimentally using two complementary preparations. In one-dimensional experiments, individual alpha-synuclein channels were incorporated into excised inside-out membrane patches from cultured hippocampal neurons. Opening of a single channel generated a pure 0.2-picoampere calcium current, matching a typical single L-type channel current. Fluorescence imaging with Fluo-4 or Fluo-4-dextran revealed localized increases in fluorescence corresponding to the formation of calcium-bound indicator molecules. Kymographs showed a progressive expansion of the fluorescence signal from the pipette tip toward the pipette interior, with the front propagating continuously away from the source rather than remaining stationary.

In two-dimensional experiments, cultured chick dorsal root ganglion neurons loaded with the same indicators were stimulated with depolarizing voltage steps that evoked whole-cell calcium currents carried predominantly by L-type channels. Fluorescence first increased beneath the plasma membrane before progressively spreading into the bulk cytoplasm as a traveling front. Pharmacological manipulation confirmed the model’s predictions: enhancement of L-type channel activity with Bay K 8644 accelerated propagation of the fluorescence front, whereas inhibition with nifedipine reduced both current amplitude and wave velocity. These effects were observed for both indicator dyes but were particularly pronounced with the slowly diffusing dextran-conjugated probe. Front position changed in proportion to the square root of time, a hallmark of diffusion processes.

The experimentally determined propagation velocities followed the theoretical trends predicted by the WKBJ analysis. Measured wave speeds ranged from approximately 114 to 477 micrometers per second depending on the indicator and pharmacological condition, agreeing qualitatively with theoretical predictions of 120 to 421 micrometers per second across parameter variations. The overall similarity between one-dimensional and two-dimensional measurements supports the conclusion that the spread of calcium-bound species represents a robust consequence of reaction-diffusion dynamics rather than a feature specific to a particular experimental geometry.

The implications for intracellular signaling are potentially far-reaching. Many endogenous calcium buffers and sensors are large proteins with limited mobility, meaning that the propagation of bound calcium may represent an efficient mechanism for long-range signaling. In this view, calcium-bound molecules rather than free calcium itself may constitute the principal carriers of information between distant intracellular sites. The duration of calcium influx may critically influence downstream signaling by determining whether sufficient sensor activation can occur before channel closure. For channels with shorter open times, such as voltage-gated calcium channels, the expansion of profiles would be terminated upon channel closure, acquiring narrower patterns whose apparent width is determined jointly by diffusion and channel open time.

Beyond calcium dynamics, the analytical framework offers a straightforward approach for incorporating diffusion into Michaelis-Menten-type reaction systems, potentially applicable to any biochemical process in which diffusion cannot be neglected. The WKBJ formalism, validated here against exact solutions for multidimensional diffusion and diffusion coupled with first-order reactions, provides simple analytical expressions that closely reproduce numerical solutions of the full reaction-diffusion system. As reaction-diffusion systems play a fundamental role in numerous biochemical and biophysical processes, this quantum-mechanics-inspired mathematical treatment may find broad application across cell biology, offering researchers a powerful new tool for understanding how signals propagate through the crowded cytoplasm.

Subject of Research: Cellular Neuroscience

Article Title: Long-range diffusion of bound Ca2+: time-dependent WKBJ solutions in one- and two-dimensional imaging

Article References: Mironov, S. L. (2026). Long-range diffusion of bound Ca2+: time-dependent WKBJ solutions in one- and two-dimensional imaging. Frontiers in Cellular Neuroscience, 20, Article 1925214. https://doi.org/10.3389/fncel.2026.1925214

Image Credits: AI Generated

DOI: 10.3389/fncel.2026.1925214

Keywords: calcium signaling, WKBJ approximation, reaction-diffusion, Michaelis-Menten kinetics, fluorescence imaging, cellular neuroscience, buffer saturation, intracellular waves, Long-range, diffusion, bound, time-dependent

The design begins with a biological insight rather than a materials problem. The team focused on microRNA-155, a short non-coding RNA molecule of just 18 to 25 nucleotides that acts as a molecular switch inside cells. Mining data from The Cancer Genome Atlas, the researchers found that miR-155 is significantly elevated in cervical cancer tissues compared with adjacent normal tissue, and that the same elevation appears in cervical cancer cell lines and in the serum of patients. A receiver operating characteristic analysis yielded an area under the curve of 0.94, indicating strong discriminative accuracy as a diagnostic biomarker. Survival curves told a darker story: patients with high miR-155 expression fared significantly worse than those with low expression, marking the molecule as a prognostic indicator as well.

But the team wanted to know what miR-155 actually does inside cervical cancer cells, not merely where it appears. Through a series of gain- and loss-of-function experiments in CaSki and SiHa cervical cancer cell lines, they showed that suppressing miR-155 slowed cell proliferation, reduced secretion of the clinical tumor marker squamous cell carcinoma antigen, and dramatically curtailed migration and invasion in Transwell and wound healing assays. Conversely, artificially boosting miR-155 made the cells more aggressive. The mechanism traced back to epithelial-mesenchymal transition, the developmental program by which cancer cells shed their adhesive, epithelial identity and acquire the motile, mesenchymal traits that enable metastasis. Overexpression of miR-155 lowered epithelial markers such as E-Cadherin, CK18 and CK19 while raising mesenchymal markers including N-Cadherin and Vimentin, along with the matrix-degrading enzyme MMP-9. Blocking miR-155 reversed the entire pattern.

To find the target through which miR-155 exerts these effects, the researchers cross-referenced databases and prediction tools, then validated candidates with dual-luciferase reporter assays. The answer was ZFPM2, a transcriptional regulator whose messenger RNA carries a binding site for miR-155 in its untranslated region. When miR-155 was present, luciferase activity from the wild-type ZFPM2 reporter dropped sharply; mutating the binding site abolished the effect. A second candidate, RASSF2, showed no direct interaction. ZFPM2 was confirmed to be downregulated in cervical cancer tissues and cell lines, and critically, restoring ZFPM2 expression in cells flooded with miR-155 reversed the proliferative surge and the EMT signature. Bidirectional rescue experiments, in which ZFPM2 was knocked down while miR-155 was inhibited, established a causal miR-155-ZFPM2-EMT axis driving the disease.

In vivo work reinforced the story. Nude mice bearing xenograft tumors derived from cervical cancer cells engineered to express an anti-miR-155 inhibitor developed tumors that grew more slowly and weighed substantially less than controls, with an inhibition rate of roughly 45.6 percent. Tumor tissue from these animals showed restored epithelial markers, diminished mesenchymal markers, elevated ZFPM2, and reduced activity of NF-κB signaling and Gli-1, pathways implicated in cervical cancer progression. The stage was thus set for a therapeutic that attacks miR-155 directly while simultaneously delivering chemotherapy.

The resulting nanoplatform, named MPDM, is a layered construct roughly 225 nanometers in diameter. At its core sits a spherical manganese dioxide nanoparticle, synthesized by reacting potassium permanganate with polyallylamine hydrochloride under optimized conditions that produce particles about 25 nanometers across. This core is wrapped in a shell of polydopamine, a bioinspired polymer prized for its biocompatibility and its adhesive chemistry. The polydopamine layer anchors two cargoes through complementary interactions: negatively charged DNAzyme-substrate probes bind via electrostatic attraction between the nucleic acids and protonated amino groups on the particle surface, while the aromatic rings of the polymer engage the nitrogenous bases of the probes through pi-pi stacking. Methotrexate, a classic antifolate chemotherapy drug with documented activity against advanced and recurrent cervical cancer, is loaded with an encapsulation efficiency reaching 80.15 percent at an optimal one-to-one mass ratio.

The elegance of the system lies in its trigger mechanism. Tumors are chemically distinctive environments, enriched in hydrogen peroxide and glutathione at concentrations far exceeding those of healthy tissue. When MPDM nanoparticles are endocytosed by cancer cells, these small molecules diffuse through pores and defects in the polydopamine shell and attack the manganese dioxide core, degrading it completely. The disintegration releases manganese ions, frees the DNAzyme probes and liberates methotrexate, while the loosened shell accelerates drug escape. The released manganese ions serve a second purpose: they are the essential metal cofactors that activate the DNAzyme, a catalytic single-stranded DNA molecule that, once unlocked by binding to miR-155, cleaves its substrate strand and physically separates a fluorophore from a quencher. The result is a fluorescent beacon that switches on only where miR-155 is present.

The sensing performance was striking. After screening DNAzyme and substrate pairs, the team identified a combination that responded linearly to miR-155 across a broad concentration range, with a detection limit of just 0.3 nanomolar. Specificity tests against six other microRNAs, including miR-21 and miR-205, produced no signal, and only manganese ions, among five metals tested, could activate the probe. Inside cells, the nanoparticles lit up brightly in CaSki and SiHa cancer cells while remaining nearly dark in normal cervical epithelial H8 cells, and the fluorescence tracked miR-155 levels up or down as researchers artificially manipulated them. Interestingly, the DNAzyme treats miR-155 as an allosteric trigger rather than a cleavage target: miR-155 binding unfolds the catalytic core, but the microRNA itself is depleted through functional sequestration and RNase-H-mediated degradation of the DNA-RNA duplex, silencing its oncogenic activity.

Therapeutic testing confirmed that the two modes of attack compound each other. In cultured cells, the full MPDM construct killed more cancer cells than nanoparticles carrying methotrexate alone, while leaving normal H8 cells unharmed, a selectivity attributed to tumor-triggered release rather than passive drug diffusion. Control experiments with mismatched or catalytically inactive DNAzymes confirmed that the enhancement depended on genuine miR-155 silencing. In tumor-bearing mice, intravenously injected nanoparticles accumulated preferentially in tumors, peaking at six hours, and a 21-day treatment course produced tumor inhibition rates of 41.4 percent for the DNAzyme carrier, 62.1 percent for methotrexate alone, and 86.2 percent for the combination. A Bliss independence analysis showed the observed effect exceeded the theoretical additive value of about 77.8 percent, confirming true synergy, likely because EMT suppression sensitizes cells to methotrexate-induced cell-cycle arrest.

Safety data were equally encouraging. Treated mice showed no weight loss, no hemolysis, no histological damage to heart, liver, spleen, lung or kidney, and normal serum markers of liver and kidney function. Inductively coupled plasma mass spectrometry found no significant long-term manganese accumulation in any organ, indicating efficient clearance of the released ions. The authors acknowledge that quantitative decoding of intratumoral miR-155 signals in living animals remains technically challenging due to the depth limits of optical imaging, and that the work validates the platform at the preclinical level. Still, the convergence of a validated oncogenic pathway, a tumor-responsive degradable carrier, and a synergistic dual-mode therapy offers a compelling template for theranostic nanomedicine, not only in cervical cancer but potentially in any malignancy driven by an identifiable microRNA signature.

Subject of Research: Tumor microenvironment-responsive manganese dioxide nanocarriers for miR-155 imaging-guided chemotherapy in cervical cancer

Article Title: Tumor microenvironment-responsive manganese nanocarriers for on-demand release of methotrexate and DNAzyme in MiR-155-driven cervical cancer

Article References: Yang, Z., Zhang, L., Wang, Z., Hu, C., Ruan, D., Zhang, F., Guo, B., Shen, Y., & Wang, F. (2026). Tumor microenvironment-responsive manganese nanocarriers for on-demand release of methotrexate and DNAzyme in MiR-155-driven cervical cancer. Materials Today Bio, 41, Article 103747. https://doi.org/10.1016/j.mtbio.2026.103747

Image Credits: AI Generated

DOI: 10.1016/j.mtbio.2026.103747

Keywords: cervical cancer, nanomedicine, theranostics, miR-155, DNAzyme, methotrexate, manganese dioxide, tumor microenvironment, epithelial-mesenchymal transition, ZFPM2, fluorescence imaging, drug delivery

The study, published in the journal Advanced Science, centers on a class of compounds known as luminescent organic radicals. Unlike most fluorescent molecules, which contain paired electrons in their ground state, radicals carry unpaired electrons. That unpaired electron gives them two remarkable properties at once. It allows them to emit light through a mechanism that differs from conventional fluorescence, and it makes them paramagnetic, meaning they can accelerate the relaxation of nearby hydrogen nuclei, the very property that MRI contrast agents exploit to brighten images. In principle, a single radical molecule could therefore serve both imaging modalities, something that conventional fluorescent dyes and gadolinium-based contrast agents cannot do on their own.

The challenge, as Associate Professor Ken Albrecht of Kyushu University’s Institute for Materials Chemistry and Engineering, who led the study, explains, is that the two technologies operate on fundamentally different principles. In fluorescence imaging, a molecule absorbs photons at one wavelength and re-emits them at another, and the detector captures that emitted light. MRI, meanwhile, works by detecting the nuclear spin of hydrogen atoms in the water molecules that make up most of the body’s soft tissue. A contrast agent improves the clarity of the resulting image by altering how quickly those spins relax back to equilibrium after being excited by the scanner’s radiofrequency pulses. Designing one molecule that satisfies both sets of requirements, and does so safely in a watery biological environment, has proven extraordinarily difficult.

The Kyushu-led team began with a luminescent organic radical called tris(2,4,6-trichlorophenyl) methyl, abbreviated TTM. This trityl-type radical had already shown promise in earlier work, producing fluorescence and exhibiting the paramagnetic behavior needed for MRI contrast. But there was a critical obstacle: TTM and its early derivatives were hydrophobic, meaning they repel water. In the aqueous environment of blood, cells, and interstitial fluid, hydrophobic molecules tend to clump together, lose their optical properties, and become difficult or impossible to deliver safely. For any radical-based probe to be useful in biological systems, water solubility was non-negotiable.

The path to solubility was not straightforward. The researchers’ first generation of modified molecules achieved good MRI activity but suffered from extremely weak fluorescence, a disappointing trade-off that threatened to undo the whole point of a dual-modal probe. Through iterative chemical optimization, the team systematically adjusted the molecular architecture, tuning the balance between the radical core that governs spin behavior and the substituents that govern light emission and solubility. The result of this refinement campaign was a pair of new compounds, designated TTM-trisTP3B and TTM-trisTP9B, in which the central radical is bound in three directions to water-soluble groups, shielding the hydrophobic core while preserving its electronic properties.

Both new molecules produced deep-red fluorescence in water, a region of the spectrum that is particularly valuable for biological imaging because longer wavelengths scatter less in tissue and are less likely to be masked by the autofluorescence that biological molecules naturally emit. Deep-red and near-infrared light therefore offers a better balance of penetration depth and signal clarity than the blue and green light emitted by many conventional dyes. The fact that these radicals achieve such emission while remaining fully water-soluble marks a meaningful advance over earlier hydrophobic generations of the TTM scaffold.

The performance of the new compounds in MRI tests was equally striking. When the researchers evaluated them in phantom images, the standard laboratory test beds used to characterize contrast agents before any biological application, both molecules enhanced image contrast approximately 2.5 to 4.5 times more strongly than previously reported water-soluble TTM radicals. That improvement matters because contrast enhancement is the measure by which MRI agents are judged: a stronger effect means a lower dose can be used, reducing both cost and any potential biological burden. It also suggests that the chemical modifications did not compromise the unpaired electron’s ability to interact with nearby water protons, the essential mechanism of radical-based MRI contrast.

To probe biological compatibility, the team tested TTM-trisTP3B in living cells. The molecule was confirmed to emit fluorescence around the cell nucleus, indicating that it enters cells and distributes within them rather than being excluded or immediately degraded. Encouragingly, the fluorescence persisted for at least 24 hours, a stability that would allow long-term tracking of cells in experiments. Sustained signal is a practical prerequisite for many applications, from following transplanted stem cells to monitoring the migration of immune cells, and many fluorescent probes fade far more quickly under the continuous illumination and metabolic stress of live-cell imaging.

Perhaps the most consequential aspect of the work is what the new probes do not contain. Conventional MRI contrast agents rely on paramagnetic metals, most commonly gadolinium, a heavy lanthanide element that is highly toxic in its free form and must be tightly chelated to be safe. Concerns about gadolinium retention in the brain and other tissues, along with rare but serious reactions in patients with kidney impairment, have driven a sustained search for alternatives. A metal-free contrast agent built entirely from organic elements sidesteps those concerns at the molecular level, offering the prospect of safer, less toxic imaging agents. Because the same molecule also fluoresces, a single injection could in principle serve both a whole-body MRI scan and a high-resolution fluorescence examination, a genuinely dual-modal capability.

The researchers caution that the full utility of these molecules remains to be established. Animal studies will be needed to assess how the compounds behave in a living organism, including their circulation time, biodistribution, clearance, and long-term toxicity, before any clinical relevance can be claimed. Nevertheless, the present results establish an important proof of concept for metal-free fluorescence and MRI dual-modal imaging, and they introduce a unifying strategy that could reshape how multimodal probes are designed. The implications may extend beyond medicine. Luminescent organic radicals have attracted growing attention in quantum information science, quantum sensing, and advanced electronic materials, fields where the same unpaired electrons that make these molecules useful contrast agents also make them sensitive probes of their environment. The Kyushu team suggests that their results may serve as a foundation for future quantum sensing technologies, meaning that a molecule born from the practical demands of medical imaging could ultimately find a second life at the frontier of quantum technology, where the ability to control and read out single electron spins is the currency of progress.

Subject of Research: Development of a water-soluble, metal-free luminescent organic radical for dual-modal fluorescence and MRI imaging

Article Title: A new metal-free and water-soluble molecule that can produce florescence and used as MRI contrast material

Article References: A new metal-free and water-soluble molecule that can produce florescence and used as MRI contrast material. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Kyushu University, organic radicals, TTM, fluorescence imaging, MRI contrast agent, water-soluble molecule, dual-modal imaging, metal-free probe, bioimaging, gadolinium alternatives, Advanced Science, trityl radical

The technique relies on indocyanine green, or ICG, a fluorescent tracer that has been approved for clinical use for decades. When injected into a vein, ICG binds to plasma proteins and stays within the bloodstream. Illuminated by near-infrared light, it emits a fluorescent signal that can be captured by a specialized camera system, allowing surgeons to watch blood perfusion unfold across the surface of an organ in real time. Because near-infrared light penetrates tissue more deeply than visible light and generates little background interference, the resulting images can reveal the boundary between tissue that is being fed by blood and tissue that has lost its supply.

In the study, published in BMC Pediatrics, a surgical team led by Li Tao, Xu Cao, and corresponding author Shu Dai applied this technology to ten children who underwent emergency surgery for testicular rupture between July 2023 and December 2025. During each operation, the surgeons injected ICG intravenously at a dose of 0.2 milligrams per kilogram of body weight and then used a near-infrared fluorescence imaging system to perform real-time angiography of the exposed testicle. The goal was to delineate, on the operating table and within minutes, the exact boundary between nonperfused tissue and tissue that was still receiving blood.

The results were strikingly consistent. In all ten patients, the fluorescence imaging clearly delineated the boundary between areas where fluorescence could be detected and areas where it could not. Those findings were incorporated into the surgeons’ overall intraoperative assessment and used to guide selective excision of tissue considered nonviable. Once the dead tissue had been removed, the team repaired the resulting defect using either sutures of the tunica albuginea, the tough fibrous capsule surrounding the testicle, or a patch of tunica vaginalis, the membrane that normally cushions the organ within the scrotum.

Follow-up examinations offered cautious encouragement. With a median follow-up of ten months, ranging from three to 32 months, all of the repaired testes showed regular morphology and homogeneous echogenicity on grayscale ultrasound, an indication that the tissue architecture had healed without the scarring or irregularity that often follows significant testicular injury. Color Doppler flow imaging, the standard ultrasound technique for visualizing blood flow, demonstrated normal blood flow signals in every case. No postoperative complications were documented in the available clinical records during the follow-up period.

The clinical stakes of this problem are considerable. Testicular rupture, in which blunt trauma tears the tunica albuginea and extrudes the delicate seminiferous tubules inside, is one of the most time-sensitive emergencies in pediatric urology. The viability of the gonad depends heavily on how quickly blood flow is restored and how accurately the surgeon judges which tissue can survive. Traditional assessment relies on visual inspection of color, texture, and bleeding at the cut edges, supplemented by preoperative ultrasound. These cues are notoriously subjective, and both errors carry lasting consequences: leaving devitalized tissue increases the risk of necrosis and atrophy, while over-resection removes germ cells that might otherwise have contributed to preserved fertility and hormone production.

ICG fluorescence imaging addresses that subjectivity directly by giving surgeons an objective, dynamic map of perfusion. The physics behind the technique is elegant. ICG absorbs light in the near-infrared range, around 800 nanometers, and re-emits it at slightly longer wavelengths. Because hemoglobin and water absorb relatively little light in this window, the fluorescence signal can be detected from tissue several millimeters to a centimeter beneath the surface, and the contrast between perfused and nonperfused regions appears within seconds of injection. In other surgical specialties, from colorectal anastomosis to reconstructive flap surgery, this real-time perfusion mapping has already changed intraoperative decision-making, and the Suzhou team’s work extends that logic to a delicate pediatric organ where every cubic millimeter of viable tissue matters.

The authors are careful to frame their findings as preliminary. This was a pilot feasibility study with only ten patients, conducted as a retrospective review of children who had already been treated under an approved new clinical technology application. The ethical approvals covered both the clinical use of ICG during testicular rupture surgery, granted in 2023, and the retrospective analysis of the resulting records, approved under number 2026CS087 before any data were abstracted. Because the study lacked a control group, it cannot yet demonstrate that ICG guidance improves long-term outcomes compared with conventional surgical judgment alone. The uniformly good results could reflect the imaging technique, careful patient selection, skilled surgery, or simply the natural history of promptly treated rupture. The authors explicitly state that their findings require validation in larger, controlled studies to determine the technique’s impact on long-term outcomes.

Nevertheless, the safety profile observed in this small cohort is reassuring. ICG has a long track record of clinical use, with adverse reactions generally rare and mild, and no adverse events were observed in these ten children. The dose used, 0.2 milligrams per kilogram, is modest, and the imaging procedure adds only a few minutes to an emergency operation, a meaningful consideration when ischemia time is a critical determinant of organ survival. For pediatric urologists, the appeal of the technique lies precisely in this combination of speed, simplicity, and visual clarity: a single injection and a camera turn an invisible physiological variable, blood flow, into an immediately interpretable image on the operating room monitor.

The broader significance of the study extends beyond urology. It represents part of a growing movement in surgery toward fluorescence-guided decision-making, in which molecular tracers and optical imaging replace guesswork with measurable signals. If larger trials confirm the Suzhou results, ICG imaging could become a standard adjunct in pediatric scrotal trauma, helping surgeons preserve organs that would once have been lost. For the children in this study, the glowing green map on the operating room monitor appears to have done exactly what such technology promises: it showed the surgeons where life remained in damaged tissue, and it helped them keep it. Whether that promise holds across hundreds of patients will be the question that future controlled studies must answer, but the first step has now been taken, and it was taken in glowing green.

Subject of Research: Intraoperative indocyanine green fluorescence imaging to assess tissue perfusion during pediatric testicular rupture surgery

Article Title: Indocyanine green fluorescence imaging for intraoperative assessment of tissue perfusion in pediatric testicular rupture: a pilot feasibility study

Article References: Tao, L., Cao, X., Huang, M., Wang, T., Zhang, L., Xia, H., Fu, M., Zhou, Y., Zhang, T., Yan, X., & Dai, S. (2026). Indocyanine green fluorescence imaging for intraoperative assessment of tissue perfusion in pediatric testicular rupture: a pilot feasibility study. BMC Pediatrics. https://doi.org/10.1186/s12887-026-07846-8

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07846-8

Keywords: indocyanine green, fluorescence imaging, testicular rupture, pediatric surgery, tissue perfusion, near-infrared imaging, intraoperative assessment, urology, pilot study, organ preservation, surgical imaging, BMC Pediatrics

The significance of the work lies in what it democratizes. DNA-PAINT, which stands for DNA Point Accumulation for Imaging in Nanoscale Topography, has emerged as one of the most conceptually elegant super-resolution methods available. Instead of relying on photoswitchable fluorescent proteins or dyes, it exploits the transient binding of short, dye-labeled DNA imager strands to complementary docking strands attached to the target molecule. Each binding event produces a brief flash of fluorescence, and because the strands bind and unbind repeatedly, the same target can blink thousands of times. When thousands of these stochastic flashes are localized and summed computationally, the resulting image achieves lateral localization precision better than five nanometers across fields of view as large as 100 by 100 square micrometers, and the approach can multiplex up to thirty different targets simply by changing DNA sequences.

But DNA-PAINT has a demanding appetite for optical stability. Because the technique achieves its extraordinary precision by pinpointing the center of each single-molecule flash, any drift of the sample relative to the objective lens during a minutes-long acquisition translates directly into blurred reconstructions. At the nanometer scale, even the thermal expansion of a microscope body or the slow sag of a stage can ruin an experiment. This is why the gold-standard implementations of DNA-PAINT have relied on TIRF illumination, which confines excitation light to a thin evanescent field near the coverslip surface, dramatically reducing out-of-focus background and boosting the signal-to-noise ratio of individual molecule flashes. Building such a system from scratch, with active focus stabilization, has remained complex and costly for the majority of laboratories.

The new study tackles this bottleneck head-on. The researchers started with a standard commercial epifluorescence microscope of the kind found in countless light microscopy facilities around the world, and they designed a conversion pathway that upgrades it into a stable TIRF platform suitable for single-molecule work. Rather than requiring users to rebuild the microscope’s optical path from raw components, the approach provides a practical engineering route that a competent facility can implement with accessible parts and careful alignment. The result is a system that delivers the illumination geometry and mechanical stability that DNA-PAINT and (d)STORM demand, without the price tag of a dedicated super-resolution instrument.

The centerpiece of the conversion is a novel focus-lock mechanism, engineered specifically with lateral sub-10-nanometer localization in mind. Focus locks generally work by monitoring a reference signal, often the reflection of an infrared laser from the coverslip-sample interface, and feeding corrections back to a piezoelectric stage or objective positioner to hold the focal plane constant. The team’s design optimizes this feedback loop for the particular requirements of DNA-PAINT acquisitions, where the lock must hold the sample steady not just in the axial direction but in a way that preserves lateral precision over long imaging sessions and large fields of view. By tailoring the lock to the statistics of single-molecule localization rather than treating it as an afterthought, the authors ensure that the converted microscope behaves like a purpose-built nanoscopy platform rather than a compromise.

Validating such a system requires benchmarks that leave no room for ambiguity, and the researchers turned to DNA origami nanostructures for exactly this purpose. DNA origami are self-assembled structures built from long strands of DNA folded by hundreds of short staple strands into precise two- and three-dimensional shapes, with docking sites placed at known nanometer-scale coordinates. When these structures are imaged by DNA-PAINT, the reconstructed positions of the docking sites can be compared directly with the designed geometry, providing an absolute ruler for localization precision and image fidelity. The team performed these validations in both two and three dimensions, demonstrating that their converted microscope resolves the nanoscale patterns with quality and precision comparable to state-of-the-art dedicated systems.

Crucially, the authors did not stop at artificial benchmarks. They applied the upgraded platform to multicolor neuronal samples, showing that the system can handle the messier realities of biological specimens, where autofluorescence, out-of-focus signal, and labeling variability all conspire to degrade image quality. The successful multicolor imaging of neurons demonstrates that the converted microscope is not merely a laboratory curiosity for calibrating origami rulers but a genuinely useful tool for addressing biological questions at the nanoscale, from the organization of synaptic proteins to the architecture of cytoskeletal assemblies.

The broader implications reach well beyond the laboratories involved in the study. Super-resolution fluorescence microscopy has transformed cell biology since its inception, earning the 2014 Nobel Prize in Chemistry, yet a persistent gap has remained between the laboratories that can afford cutting-edge instrumentation and those that cannot. Methods like DNA-PAINT lowered the barrier on the chemistry side by replacing specialized photoswitching buffers and genetically encoded tags with simple DNA reagents. This new work lowers the barrier on the hardware side, attacking the last major source of cost and complexity. A facility that already owns a conventional epifluorescence stand can now, in principle, join the nanoscale imaging community with a modest investment and a well-documented conversion procedure.

The collaborative character of the project is itself instructive. The research brought together groups spanning Montevideo, Buenos Aires, Bern, Würzburg, and Planegg, combining expertise in microscopy engineering, DNA nanotechnology, and neuroscience. The authors acknowledge support from national funding agencies and foundations in Uruguay, Argentina, and Europe, including the Agencia Nacional de Investigación e Innovación, PEDECIBA, the Alexander von Humboldt Foundation, and the Wellcome Trust, illustrating how internationally distributed teams can pool resources to solve problems that individual laboratories in less well-funded regions would struggle to tackle alone. The paper also benefited from careful reading by leading figures in the single-molecule microscopy community, underscoring the collaborative ethos of the field.

Published open access in Communications Engineering, the study arrives at a moment when the demand for nanoscale structural information in biology is accelerating. Understanding how proteins organize into complexes, how synaptic architectures change during learning, and how molecular machines assemble inside cells all require resolving powers that conventional diffraction-limited microscopy, capped at roughly 250 nanometers, simply cannot deliver. By showing that a routine fluorescence microscope can be transformed into a sub-10-nanometer localization platform, the researchers have effectively multiplied the number of laboratories capable of contributing to these questions. For facility managers weighing whether to invest hundreds of thousands of dollars in a dedicated TIRF nanoscopy system, and for researchers in institutions where such budgets are unthinkable, this work offers a compelling alternative: the nanoscale revolution, it turns out, may be one careful microscope conversion away.

Subject of Research: Converting conventional fluorescence microscopes into high-performance platforms for sub-10-nm single-molecule localization microscopy

Article Title: Converting a conventional fluorescence microscope into a high-performance platform for sub-10-nm single-molecule localization microscopy

Article References: Garat, J., Oliveira-Rizzo, C., Bentancor, M., Arredondo, F., Sotelo-Silveira, J., Masullo, L. A., & Di Paolo, A. (2026). Converting a conventional fluorescence microscope into a high-performance platform for sub-10-nm single-molecule localization microscopy. Communications Engineering. https://doi.org/10.1038/s44172-026-00765-7

Image Credits: AI Generated

DOI: 10.1038/s44172-026-00765-7

Keywords: super-resolution microscopy, DNA-PAINT, single-molecule localization microscopy, TIRF, focus lock, epifluorescence microscope, DNA origami, (d)STORM, fluorescence imaging, nanoscopy, microscopy hardware, open access

The commentary responds to a short communication by Hamm and colleagues describing computed tomography-guided percutaneous marking of lung nodules using two well-established agents: patent blue V, a visible dye, and indocyanine green, a fluorescent tracer that glows under near-infrared light. The German team also explored indocyanine green-soaked coils, small metallic spirals drenched in the fluorescent dye before deployment. In their reported series, all patients underwent complete resection without conversion to open surgery, a result the commentary authors describe as underscoring the technical reliability of the approach. What makes the technique attractive, they note, is its accessibility and workflow flexibility: the marking is performed percutaneously in the radiology suite, avoiding rigid transpleural devices that must stay in place until resection, and eliminating the need for intraoperative fluoroscopy altogether.

That last point matters more than it might first appear. Robotic-assisted thoracic surgery has transformed minimally invasive lung resection, offering articulated instruments, high-definition three-dimensional vision, and steady precision within a confined chest cavity. But robotic operating environments are notoriously unfriendly to techniques that require a fluoroscope to be wheeled in mid-operation. Hybrid operating rooms equipped with integrated imaging remain scarce and expensive, particularly outside major academic centres. A localisation strategy that relies on preoperative computed tomography guidance and then hands off to near-infrared fluorescence, which integrates seamlessly into robotic camera platforms, preserves operative ergonomics and could allow hospitals without hybrid theatres to offer minimally invasive sublobar resection to their patients. In this sense, the commentary frames computed tomography-guided fluorescence as a platform technology reinforcing the expanding role of interventional radiology in precision thoracic oncology.

To understand where the field is heading, the authors propose a generational framework for pulmonary localisation strategies. The first generation was hook-wire localisation, in which a thin wire with a hooked tip is placed into or adjacent to the nodule under imaging guidance. Wires are effective but carry well-known drawbacks: they can displace, they puncture the pleura and can cause pneumothorax, and the rigid external component must be managed carefully until the surgeon removes it. The second generation was percutaneous dye injection, simple and cheap, but vulnerable to two failure modes: dyes diffuse through the soft lung parenchyma and they fade over time, so the target zone a surgeon sees may no longer correspond to where the dye was originally placed. The third generation introduced coil-assisted fluorescence, in which a metallic coil provides mechanical containment for the fluorescent dye, improving durability and visibility.

It is the fourth generation, still emerging, that excites the commentary’s authors most: stabilised fluorescent matrices designed to optimise spatial fidelity. The central insight is that diffusion control is not a minor technical detail but the very heart of localisation accuracy. When liquid dye is injected into lung tissue, it spreads laterally through the interstitium, creating a fluorescent zone that grows and blurs over time. Visibility without spatial fidelity, the authors warn, risks misleading surgical guidance. In a lobectomy, where the entire lobe is removed, a few millimetres of dye drift are inconsequential. But in a sublobar resection, a segmentectomy or wedge resection intended to preserve as much healthy lung as possible, margin geometry is everything. If the fluorescent cloud has migrated, the surgeon may resect around the wrong centre, compromising the distance between the tumour edge and the cut margin.

The stakes of margin integrity have been raised sharply by randomised evidence. The Japanese JCOG0802/WJOG4607L trial, a multicentre phase 3 study published in The Lancet in 2022, demonstrated that segmentectomy is non-inferior to lobectomy for small peripheral non-small-cell lung cancer, validating lung-preserving surgery for selected early-stage patients. That victory for tissue-sparing oncology, however, makes the localisation problem more acute rather than less. When the goal shifts from removing an entire lobe to carving out a precise wedge around a ten-millimetre lesion, the surgeon depends absolutely on the fidelity of whatever marker was placed the day before. Margin distance and local recurrence become the decisive metrics, and any localisation technique that cannot guarantee spatial accuracy becomes the weak link in an otherwise elegant chain.

This is why the commentary insists that future localisation research be framed by oncologic endpoints rather than technical success alone. Viana and Nunes call for systematic reporting of lesion depth, minimal margin distance, and longitudinal local recurrence in every study of nodule marking. Complete resection rates, while reassuring, are a blunt instrument; a resection can be complete yet carry a margin so narrow that recurrence risk rises. They also urge multicentre prospective validation within robotic workflows, recognising that single-centre feasibility studies, however encouraging, cannot establish whether a technique performs consistently across different operators, scanner platforms, and patient anatomies. Whether molecular stabilisation of fluorescent dyes translates into superior oncologic precision, they acknowledge, requires exactly this kind of prospective evaluation, but the conceptual evolution is notable.

The stabilised matrix concept represents a genuinely biochemical approach to a problem that previous generations attacked mechanically. Rather than containing dye with a coil or accepting its diffusion as inevitable, these formulations modulate dye distribution at the injection site itself, reducing lateral spread and potentially improving margin predictability. The commentary’s authors have direct experience in this territory: they previously published a technical note on computed tomography-guided dual-fluorescent marking for robotic sublobar resection covering 84 consecutive cases, work cited in their commentary as part of the field’s progression. Their argument is that these four generations, hook-wires, dye injections, coil-assisted fluorescence, and stabilised matrices, should be understood not as competitors but as iterative refinements, each responding to a clearly identified limitation of its predecessor.

For readers wondering why this seemingly niche surgical debate deserves broader attention, the answer lies in the convergence of three trends that are reshaping cancer care worldwide. Screening programmes are expanding, which means more small nodules will be found and more of them will be operated on. Robotic platforms are proliferating, which means more of those operations will be performed with instruments that cannot palpate a lesion hidden in deflated lung tissue. And lung-preserving resection is gaining evidence-based legitimacy, which means the precision demands on localisation will only intensify. The commentary’s closing line captures the moment succinctly: if feasibility has defined the past decade of computed tomography-guided localisation, precision will define the next. What began as a practical question of how to mark a spot in the lung is maturing into a rigorous discipline of spatial oncology, where the biochemistry of a dye, the geometry of a surgical margin, and the long-term risk of cancer recurrence are inseparably linked.

There are, of course, caveats that the commentary itself makes explicit. The heterogeneity of marking techniques currently in use, spanning simple dye injection and coil-assisted fluorescence, reflects an important developmental phase but may limit standardisation, making head-to-head comparisons difficult. The stabilised fluorescent matrices remain conceptually promising rather than prospectively proven, and their advantage over coil containment must be demonstrated in controlled studies. Nor does the commentary claim that any single technique is universally superior; instead, it offers a roadmap for how the field should evaluate its options. For a specialty in which a few millimetres of tissue can determine whether a patient keeps half a lung or loses a whole one, that shift in standards, from visible to verifiable, from feasible to faithful, may prove to be the most consequential development in thoracic surgical oncology this decade.

Subject of Research: Computed tomography-guided fluorescent localisation of small pulmonary nodules for robotic thoracic surgery

Article Title: Evolving generations of computed tomography-guided lung nodule localisation toward stabilised fluorescent precision in robotic thoracic oncology

Article References: Viana, P. C. C., & Nunes, T. F. (2026). Evolving generations of computed tomography-guided lung nodule localisation toward stabilised fluorescent precision in robotic thoracic oncology. CVIR Oncology, 2(1), Article 31. https://doi.org/10.1007/s44343-026-00036-4

Image Credits: AI Generated

DOI: 10.1007/s44343-026-00036-4

Keywords: lung nodule localisation, computed tomography guidance, indocyanine green, patent blue V, fluorescence imaging, robotic thoracic surgery, sublobar resection, segmentectomy, surgical margins, interventional radiology, precision oncology, stabilised fluorescent matrices

In a pilot study published in Holistic Integrative Oncology, researchers from Liaoning Cancer Hospital and Dalian University of Technology evaluated a sprayable fluorescent probe that targets gamma-glutamyl transpeptidase, an enzyme abbreviated γ-GGT or GGT2. The enzyme sits on the membranes of mammalian cells and is normally abundant in secretory organs such as the liver, kidney, and pancreas, but its expression and activity rise sharply in many malignancies, including liver, lung, colorectal, breast, and ovarian cancers. Previous work has suggested that γ-GGT helps tumors progress, invade, and resist chemotherapy by reshaping intracellular redox metabolism, and elevated pretreatment serum levels of the enzyme have been linked to advanced stage and poor prognosis in epithelial ovarian cancer. That combination of high tumor expression and clinical relevance made γ-GGT an attractive molecular bullseye for intraoperative imaging.

The probe itself, designated NIR-SN-GGT, is a product of a medical-engineering collaboration between the cancer hospital and the State Key Laboratory of Fine Chemicals in Dalian. Chemically, it couples a dicyanoisophorone-based near-infrared fluorophore to a γ-glutamyl recognition unit through an amide bond. In its intact state the molecule is essentially dark: the γ-glutamyl group acts as an electron-withdrawing quencher that suppresses intramolecular charge transfer, the process responsible for fluorescence. When the probe encounters γ-GGT on the surface of a cancer cell, the enzyme cleaves the γ-glutamyl bond, releasing a free amine that restores charge transfer and triggers a rapid turn-on fluorescence signal in the near-infrared region, with an emission maximum around 650 nanometers, excitation near 445 nanometers, and a large Stokes shift of roughly 205 nanometers. Because the reaction occurs only where the enzyme is abundant, background fluorescence in healthy tissue stays negligible, which is precisely what a surgeon needs to distinguish tumor from normal tissue in real time.

Crucially, the team did not stop at cell cultures or mouse models, the point at which most targeted fluorescent probes have historically stalled. Instead, they built a three-tier validation pipeline that moved from bioinformatics to organoids, then to frozen tissue sections, and finally to fresh human specimens removed during surgery. Analysis of The Cancer Genome Atlas confirmed elevated GGT2 mRNA in ovarian tumors compared with normal ovary, and immunohistochemistry on archival paraffin blocks from 36 high-grade serous ovarian cancer cases showed robust γ-GGT protein on cancer cell membranes. The researchers then grew patient-derived ovarian cancer organoids in three-dimensional matrix cultures and observed distinct probe fluorescence within these miniature tumors, confirming that the probe can label γ-GGT-positive cells in a system that mimics the tumor microenvironment far better than flat cell monolayers.

The next tier involved frozen sections cut at 100-micrometer thickness from freshly resected cancer and pericancerous tissue. After spraying the sections with a 10 micromolar probe solution and waiting just one minute, confocal microscopy revealed a fluorescence pattern that colocalized almost perfectly with DAB immunostaining for γ-GGT, with markedly stronger signal in cancerous regions than in adjacent non-cancerous tissue. This spatial agreement between enzyme activity imaging and classical pathology provided the bridge from in vitro validation to real human tissue, setting the stage for the ex vivo experiments that form the heart of the study.

Between February and November 2023, the team collected fresh tissue from 16 patients aged 46 to 77 who underwent primary, interval, or secondary cytoreductive surgery for epithelial ovarian cancer, most of them at advanced FIGO stage III or IV. From these patients they harvested 42 confirmed cancerous lesions, including 18 primary ovarian lesions, 15 omental metastases, and 9 peritoneal metastases, spanning diameters of 0.5 centimeters, 0.3 centimeters, and smaller than 0.3 centimeters. Each specimen was sprayed with probe solution at 1, 5, or 10 micromolar within 30 to 40 minutes of resection, then imaged every minute for half an hour and again at one hour and five hours using a simple setup: an iPhone 12 mini camera fitted with an emission filter, working at a distance of 15 to 20 centimeters under dark conditions. Signal-to-background ratios, calculated as average lesion fluorescence divided by average fluorescence of surrounding normal tissue, served as the primary metric, with values above 1.2 considered visible to the naked eye.

The optimization experiments delivered clear answers. Across all 42 lesions, every sample produced a signal-to-background ratio above 1, yielding 100 percent fluorescence detection, and 95.2 percent were visible without any image processing. The 10 micromolar concentration proved to be the minimum effective dose, achieving signal-to-background ratios of 1.40 plus or minus 0.17 for primary lesions and 1.32 plus or minus 0.12 for omental metastases, significantly better than the 1.17 and 1.27 values seen at lower concentrations. Just as importantly, the imaging window proved remarkably forgiving: fluorescence appeared within one minute of spraying and remained stable from one minute to one hour, with ratios hovering between 1.26 and 1.29, before fading by five hours. Lesion size made no difference, with sub-0.3-centimeter implants imaged just as brightly as larger ones, a finding with obvious implications for catching the millimeter-scale seedings that surgeons most often miss.

The clinical validation phase then put the optimized protocol to the test on 27 sub-0.3-centimeter lesions from 8 patients, along with adjacent normal tissues and a negative control of normal peritoneum. Fluorescence imaging identified 26 of the 27 cancerous lesions, a true-positive rate of 96.3 percent, and 23 lesions were visible to the naked eye, a macroscopic detection rate of 81.5 percent. Only one false positive appeared, in a sample of normal peritoneal tissue that pathology confirmed lacked γ-GGT expression; the spurious signal was attributed to residual red blood cells on the tissue surface, whose protoporphyrin content autofluoresces in the same spectral region. Immunohistochemistry confirmed membrane γ-GGT expression in 100 percent of cancerous lesions in both cohorts while normal tissues stained negative, underscoring the target’s specificity. The authors note that meticulous intraoperative hemostasis and thorough saline rinsing of tissue surfaces before spraying are essential precautions to keep blood-related false positives in check.

Statistical analysis of the clinical variables added a note of caution for future use. Univariate analysis found that preoperative serum γ-GGT levels and treatment modality both influenced imaging quality, with patients whose serum levels reached at least 20 units per liter showing higher signal-to-background ratios. In multivariate analysis, only the preoperative treatment approach remained independently predictive, most likely because neoadjuvant chemotherapy can reduce γ-GGT expression or activity in tumor tissue and thereby weaken probe binding. Encouragingly, clinical stage, lesion location, and pathological type did not alter probe performance, suggesting the technique is robust across the diverse clinical presentations of ovarian cancer.

The authors are candid about the study’s limits. The cohort of 16 patients is too small for firm statistical conclusions, and larger trials will be needed to stratify effects of specific chemotherapy regimens and timing of interval surgery. The single false negative occurred in a γ-GGT-positive lesion buried more than three millimeters beneath the tissue surface, a reminder that near-infrared light at 650 nanometers penetrates tissue only shallowly; deeper lesions may require surgical exposure or next-generation probes emitting in the second near-infrared window above 1000 nanometers. Standardized fluorescence evaluation criteria will also be needed to reduce observer variability. Even so, the head-to-head comparison is striking: the FDA-approved folate receptor-alpha probe pafolacianine detects ovarian cancer lesions with 83.0 percent sensitivity and a 32.7 percent false-positive rate, whereas the sprayed γ-GGT probe achieved a 98.6 percent true-positive rate with only a 1.4 percent false-positive rate in the ex vivo experiments, while topical delivery slashes the dose required compared with intravenous agents and reduces the risk of systemic toxicity. If larger clinical trials confirm these results, a bottle of enzyme-activated dye and a filtered smartphone camera could one day become standard equipment in the fight against one of medicine’s most elusive cancers.

Subject of Research: Sprayable γ-GGT-activated fluorescent probe for intraoperative visualization of epithelial ovarian cancer

Article Title: Exploration of the application of the sprayed γ-GGT fluorescent probe for visual imaging of epithelial ovarian cancer: a pilot study

Article References: Liu, Z., Zhang, M., Li, H., Liu, L., Chen, F., Li, M., Gao, Y., Wang, D., & Yang, Z. (2026). Exploration of the application of the sprayed γ-GGT fluorescent probe for visual imaging of epithelial ovarian cancer: a pilot study. Holistic Integrative Oncology, 5(1), Article 46. https://doi.org/10.1007/s44178-026-00268-7

Image Credits: AI Generated

DOI: 10.1007/s44178-026-00268-7

Keywords: ovarian cancer, fluorescent probe, gamma-glutamyl transpeptidase, fluorescence imaging, intraoperative imaging, cytoreductive surgery, organoids, signal-to-background ratio, near-infrared fluorescence, tumor imaging, pafolacianine, precision oncology

The two ingredients are sorafenib, a multikinase inhibitor used clinically against liver and other cancers, and curcumin, the polyphenolic compound extracted from turmeric rhizome that has long attracted interest for its anticancer properties. Both drugs share a frustrating limitation: patients frequently develop resistance to sorafenib after prolonged treatment, while curcumin suffers from poor solubility and weak fluorescence. The researchers dissolved the two molecules in dimethyl sulfoxide and injected the solution dropwise into water. As the proportion of water rose, the molecules spontaneously clustered into spherical nanoparticles roughly 286 nanometers in diameter, with a narrow size distribution and a strongly negative surface charge consistent with good biocompatibility.

What makes these particles remarkable is that neither drug fluoresces meaningfully on its own. Free curcumin actually loses its weak emission when it aggregates, a phenomenon known as aggregation-caused quenching, and sorafenib is similarly dark. Yet when the two co-assemble, the resulting nanoparticles emit bright light, a behavior the authors describe as a 0 + 0 > 2 fluorescence effect and term pharmaceutical dots-induced emission. Spectroscopic analysis revealed why: the pyridine ring of sorafenib stacks against the aromatic rings of curcumin through pi-pi interactions, while hydrogen bonds form between curcumin’s ketonic groups and sorafenib’s nitrogen atoms. Molecular dynamics simulations running over 50 nanoseconds showed the drugs first clustering separately and then merging into a stable core-shell architecture, with fluorine and chlorine atoms from sorafenib concentrated in the core and curcumin woven throughout.

The practical advantages of this carrier-free design are substantial. Traditional nanocarriers often achieve drug loadings below 10 percent because the carrier material dilutes the payload, but the self-assembled particles reached encapsulation efficiencies above 98 percent for both drugs, with sorafenib loading at 78 percent and curcumin at 14 percent. The particles also exhibited a large Stokes shift of 130 nanometers, which minimizes self-absorption and background autofluorescence, and their emission position stayed fixed across excitation wavelengths, a property that simplifies high-precision bioimaging. Stability tests in serum showed no change in particle size or fluorescence over extended periods, and in tumor-bearing mice the nanoparticles produced strong detectable signals in the lungs where a simple drug mixture produced none.

But the imaging capability turned out to be only the opening act. When the researchers treated breast cancer 4T1 cells and human liver cancer MHCC-97H cells with the nanoparticles, transmission electron microscopy revealed something unexpected: lysosomes and mitochondria, the cell’s digestive and energy-producing organelles, migrated toward the nucleus and clustered tightly around it. In untreated cells, mitochondria sat an average of 242 nanometers from one another and more than 225 nanometers from the nucleus. After treatment, those distances collapsed to roughly 17, 22 and 45 nanometers respectively, close enough to constitute direct interorganelle contact sites. Structured illumination microscopy and confocal imaging of the organelle marker proteins LAMP1, TOMM20 and Lamin B1 confirmed the same tripartite lysosome-mitochondrion-nucleus contacts in both cell lines and later in metastatic lung tissue.

To understand what these contacts accomplish, the team turned to proteomics. Quantitative mass spectrometry identified 2,244 differentially expressed proteins after nanoparticle treatment, with gene ontology analysis showing that the altered proteins concentrated in the nucleus, cytoplasm and mitochondrion. Upregulated proteins enriched in mitochondrial functions such as oxidative phosphorylation and NADH dehydrogenase activity, while downregulated proteins clustered around nuclear processes including DNA replication, cell cycle transitions and epigenetic regulation. Cross-referencing the differentially expressed proteins against survival genes from breast cancer patient data pointed to a single nuclear suspect: histone deacetylase 2, or HDAC2, an epigenetic enzyme whose overexpression is associated with poor outcomes and metastatic progression in breast cancer patients.

The mechanistic picture that emerged links organelle geometry to gene regulation. Mitochondria are the primary generators of reactive oxygen species, and lysosomes can amplify mitochondrial ROS production. By herding both organelles against the nuclear membrane, the nanoparticles appear to deliver a concentrated burst of ROS directly into the nucleus. Flow cytometry of isolated nuclear fractions confirmed elevated nuclear ROS after treatment, and the signal scaled with both dose and time. That nuclear ROS, the researchers found, suppresses HDAC2. When they scavenged ROS with N-acetylcysteine, HDAC2 expression rebounded; when the nanoparticles were present, ROS climbed and HDAC2 fell again. Conversely, blocking HDAC2 directly with the approved inhibitor vorinostat reproduced the antimigratory effect, confirming HDAC2 as a functional node rather than a bystander.

The downstream consequence is the collapse of epithelial-mesenchymal transition, the cellular program that allows cancer cells to detach, invade and colonize new tissue. Treated cells showed restored E-cadherin, the adhesion molecule lost during metastatic conversion, and reduced Vimentin, the motility marker that rises as cells turn invasive. Wound healing assays told the story in numbers: untreated cells closed a scratch almost completely within 24 hours, free sorafenib slowed closure to about 52 percent, the drug mixture to 34 percent, but the nanoparticles cut it to roughly 11 percent. Transwell invasion assays, western blots and immunofluorescence all corroborated the shift, and the nanoparticles also preserved sorafenib’s original function, suppressing phosphorylation of VEGFR and ERK while additionally sensitizing cells to mitochondrial ferroptosis through effects on GPX4 and DHODH.

In vivo, the strategy proved itself in mouse models of breast cancer lung metastasis. When 4T1 cells pretreated with the nanoparticles were injected into mice, lung weights and histopathology showed dramatically fewer metastatic lesions than with either drug alone. In a therapeutic model using luciferase-labeled 4T1 cells, intravenous dosing every two days for five doses produced significant reductions in tumor burden, metastatic nodule counts and bioluminescent signal compared with paclitaxel, curcumin or sorafenib, and paclitaxel itself has been reported to worsen metastasis in some models. Immunohistochemistry of metastatic lungs confirmed the same molecular signature seen in culture: high E-cadherin, low Vimentin, suppressed HDAC2, and dense perinuclear clusters of lysosomes and mitochondria. Body weights remained stable throughout, and histological and serum chemistry analyses of major organs showed no pathological damage, with liver and kidney markers staying within normal ranges.

The study’s broader significance lies in its demonstration that organelle positioning, not just molecular targeting, can be a therapeutic lever. Cancer cells depend on coordinated communication among lysosomes, mitochondria and the nucleus, yet these tripartite contacts had remained largely unexplored as drug targets. By pairing a kinase inhibitor with a dietary polyphenol in a carrier-free assembly, the researchers achieved simultaneous multi-target action, real-time imaging and a previously uncharacterized nuclear ROS-HDAC2-EMT axis, all without the cytotoxic residues that chemical fluorescent labeling would introduce. The work remains at the preclinical stage, and the specific drug pair was chosen partly for its assembly chemistry, but the concept of converting drug molecules themselves into self-reporting, organelle-orchestrating therapeutics opens a genuinely new direction for antimetastatic drug design, one where the medicine and the microscope share the same molecule.

Subject of Research: A carrier-free supramolecular nanoassembly of sorafenib and curcumin that inhibits tumor metastasis through lysosome-mitochondrion-nucleus contacts and a nuclear ROS-HDAC2-EMT signaling axis

Article Title: A label-free supramolecular nanoassembly triggers multi-organelle crosstalk-dependent metastasis inhibition via nuclear ROS-HDAC2 axis

Article References: Wang, R., Zou, L., Mi, D., Wang, C., Song, Z., Liu, T., Zhao, M., Wang, D., & Shi, S. (2026). A label-free supramolecular nanoassembly triggers multi-organelle crosstalk-dependent metastasis inhibition via nuclear ROS-HDAC2 axis. Materials Today Bio, 41, Article 103681. https://doi.org/10.1016/j.mtbio.2026.103681

Image Credits: AI Generated

DOI: 10.1016/j.mtbio.2026.103681

Keywords: sorafenib, curcumin, self-assembly, nanoparticles, metastasis, lysosome-mitochondria contacts, nuclear ROS, HDAC2, epithelial-mesenchymal transition, pharmaceutical dots, fluorescence imaging, breast cancer

The report, led by interventional radiologist Charlie A. Hamm and colleagues, is framed as a technical roadmap rather than a large trial, but its results are striking in their consistency. Eleven patients, four women and seven men ranging in age from 34 to 77, underwent CT-guided dye-based marking of twelve lung nodules before minimally invasive, lung-sparing resection. The median nodule diameter was just 8.5 millimeters. Every single marking procedure was technically successful, every lesion was completely resected, and no operation had to be converted to open surgery or an entire lobectomy because the surgeon could not find the target. Seven of the twelve lesions turned out to be malignant, underscoring how much rides on getting the localization right.

The clinical backdrop explains why this matters. Randomized screening trials such as the Dutch-Belgian NELSON study showed that volume-based CT screening reduces lung cancer mortality, and more recent cohort work like the SUMMIT study has confirmed that the majority of screen-detected cancers are diagnosed at stage I or II, when surgery is the primary treatment. That shift has pushed thoracic surgeons toward sublobar resection, removing a wedge of lung or a single segment rather than the whole lobe, to preserve as much healthy parenchyma as possible. But the smaller the lesion and the more tissue-sparing the operation, the more critical it becomes to know exactly where the target sits before the first incision is made.

The traditional answer has been the hook-wire, a thin barbed wire placed through the chest wall into or next to the nodule on the morning of surgery. Hook-wires work, but they come with real drawbacks. They typically force same-day scheduling of two procedures, they can dislodge or migrate before the surgeon reaches them, and a rigid wire protruding through the pleura is uncomfortable and potentially hazardous for the patient, who must be transported carefully to avoid tearing lung tissue. The Berlin team’s dye-based approach eliminates the transpleural hardware entirely, which the authors note has been reported to cause less patient discomfort and stress and reduces the risk of marker displacement.

The first of the two dye techniques relies on patent blue V, a synthetic triphenylmethane dye that has long been used to trace lymphatic drainage in breast surgery and melanoma staging. It is water-soluble, renally excreted, and has a low toxicity profile, with allergic reactions occurring in fewer than one percent of patients. Under CT-fluoroscopic guidance, the radiologist advances a fine 22-gauge Chiba needle until its tip sits immediately adjacent to the nodule, deliberately avoiding puncture of the lesion itself, which reduces the theoretical risk of tumor seeding along the needle track and avoids compromising the pathology specimen. Then 0.1 to 0.4 milliliters of dye is injected through a small Luer-lock syringe, and the needle is withdrawn promptly without a saline flush, which would dilute the dye and could tattoo the skin along the exit path.

What happens next is a matter of physics and anatomy. The dye diffuses through the terminal vascular bed of the lung and reaches the pleural surface, where it creates a sharply demarcated blue patch that tells the surgeon precisely where the resection margin should fall. If the lesion lies more than three centimeters beneath the pleura, the dye is injected in increments as the needle is withdrawn, leaving a stained tract running from the nodule toward the chest wall. Because patent blue V gradually disperses into the bloodstream and pleural fluid, the color fades within hours, so surgery must be scheduled the same day, ideally within three hours of the marking. In the Berlin series, the five patients who received patent blue V injections had a median marking time of just seven minutes.

The second technique solves the fading problem with indocyanine green, or ICG, a tricarbocyanine fluorescent dye that binds readily to tissue proteins and glows bright emerald green when excited by near-infrared light. Injected alone, ICG diffuses more slowly than patent blue V and can remain visible in lung tissue for up to six days, a finding documented in prior experimental work. More importantly, near-infrared light penetrates soft tissue far better than visible light, so a fluorescence camera in the operating room can detect the glowing signal from millimeters to several centimeters beneath the pleural surface, effectively letting the surgical team see through the lung’s outer rim to a depth of roughly three centimeters. The six patients in the series who received ICG-based marking had a median procedure time of 16.5 minutes.

The most innovative variant described in the report goes one step further: instead of injecting liquid dye that will eventually disperse, the team deploys a tiny embolization coil soaked in ICG. The preparation is meticulous. ICG is mixed with ten milliliters of sterile water, and two to three milliliters of the solution are used to slowly flush the coil introducer outside the patient to prevent premature deployment. The markers are Tornado-type coils measuring 0.035 inches in diameter and 7 to 8 millimeters in length. After percutaneous puncture with an 18-gauge coaxial needle, the coil is advanced with the stiff end of a guidewire and deployed under CT-fluoroscopy immediately adjacent to the lesion, with care taken not to push it too far past the target. The coil acts as a physical scaffold that holds the dye in place, and because the fluorescence persists for days, surgery can be scheduled up to thirteen days after marking, giving hospitals valuable flexibility when operating rooms are crowded or schedules shift unexpectedly.

Safety data from the series align with the broader literature. Only one complication occurred, an asymptomatic pneumothorax during needle puncture that was managed conservatively without any intervention, consistent with reported pneumothorax rates of around six percent for CT-guided ICG injection in a retrospective analysis of 471 patients. The authors do caution that coil placement requires a larger 18-gauge needle than pure dye injection, which may influence complication rates. Prior studies have reported technical success rates above 98 percent for CT-guided dye injection and 100 percent for bronchoscopy-guided ICG-coil placement, and the addition of preoperative markings has been shown in other reports to drive conversion rates to open surgery close to zero.

What makes the Berlin report notable is the delivery route. ICG-soaked coil marking had previously been described through bronchoscopy, a technique that requires general anesthesia and specialized endoscopic equipment, and only recently through a percutaneous approach. The CT-guided percutaneous route can be performed in an outpatient workflow under local anesthesia alone, making it less resource-intensive and easier to slot into a busy hospital schedule. The authors emphasize that the technique is ultimately a story about multidisciplinary collaboration: the tumor board decides the patient needs lung-sparing surgery, the interventional radiologist plants the beacon, and the thoracic surgeon follows the glow. As robotic-assisted and uniportal thoracoscopic surgery become more common and screening programs continue to surface ever-smaller nodules, dye-based marking may become a routine bridge between the radiology suite and the operating room, turning invisible targets into ones a surgeon cannot miss.

Subject of Research: CT-guided preoperative dye-based marking of small lung nodules for minimally invasive surgical resection

Article Title: CT-guided percutaneous marking of lung nodules using patent blue V and indocyanine green

Article References: Hamm, C. A., Elsner, A., Fehrenbach, U., Savic, L. J., Bawaadam, H., Collettini, F., Neudecker, J., Gebauer, B., Rückert, J., & Auer, T. A. (2026). CT-guided percutaneous marking of lung nodules using patent blue V and indocyanine green. CVIR Oncology, 2(1), Article 2. https://doi.org/10.1007/s44343-026-00031-9

Image Credits: AI Generated

DOI: 10.1007/s44343-026-00031-9

Keywords: lung nodules, interventional radiology, indocyanine green, patent blue V, CT guidance, thoracic surgery, fluorescence imaging, preoperative localization, lung cancer screening, video-assisted thoracoscopic surgery, fiducial coils, lung-sparing resection

The central innovation behind SPIFFI lies in its use of polarimetry, the measurement and manipulation of the polarization state of light, as a vehicle for encoding information that would normally require repeated measurements to capture. In conventional fluorescence imaging, the polarization of emitted or illuminated light is often treated as a nuisance parameter to be minimized or ignored. SPIFFI instead treats polarization as a rich information channel. By carefully structuring the polarization of light interacting with the sample, and by decoding the resulting polarization-dependent patterns, the technique extracts sub-diffraction-scale spatial information from what would otherwise be a single, ordinary-looking frame of data.

To understand why this matters, it helps to recall how super-resolution microscopy typically works. Techniques such as structured illumination microscopy overlay known patterns onto the sample, and the interaction between the illumination pattern and fine sample structure shifts normally invisible high-frequency information into the observable range. Capturing that information, however, usually demands multiple raw images taken with the pattern shifted and reoriented, phase stepping through several positions before a reconstruction algorithm can assemble a super-resolved result. Each additional frame adds exposure time, phototoxicity, and sensitivity to sample motion. In a living cell that is crawling, dividing, or trafficking vesicles along microtubules, even a few tens of milliseconds between frames can smear fine structures into unrecognizable streaks.

SPIFFI’s single-shot design sidesteps this problem by ensuring that all the information needed for super-resolution reconstruction is packed into one exposure. Rather than stepping through illumination phases sequentially, the system encodes the necessary spatial and polarization diversity simultaneously, so that a single camera frame contains, in a multiplexed form, the data that earlier approaches gathered across multiple frames. Decoding software then computationally separates the multiplexed channels and reconstructs a super-resolved image, along with additional multidimensional information about the sample. The practical consequence is that researchers can follow fast biological processes with spatial resolution beyond the diffraction limit while acquiring images at video rates or faster, limited primarily by camera speed and signal brightness rather than by the imaging protocol itself.

The multidimensional character of the technique is one of its most striking features. Beyond simply sharpening the lateral position of fluorescent structures, SPIFFI’s polarimetric readout carries information about additional dimensions of the light field, which can be exploited to characterize properties of the sample or the fluorescent labels themselves. Fluorescent molecules do not emit light uniformly in all directions; their emission and excitation depend on the orientation of their dipoles, and the polarization of fluorescence therefore encodes molecular orientation information. In many biological contexts, from the tilt of transmembrane proteins to the architecture of cytoskeletal filaments, this orientation information is biologically meaningful. A technique that retrieves it simultaneously with super-resolved spatial position, in real time, opens the door to imaging modalities in which each frame conveys a richer picture of molecular-scale organization than a conventional intensity image ever could.

The implications for live-cell imaging are substantial. Dynamic processes that have been particularly challenging for super-resolution methods include the remodeling of the actin cortex during cell migration, the rapid exchange of proteins at synapses, membrane fusion and fission events, and the motion of molecular motors along cytoskeletal tracks. In each case, the structures involved are small enough to demand super-resolution, yet fast enough that sequential multi-frame acquisition would blur them. Single-shot acquisition removes the temporal bottleneck: because the entire measurement occurs within one exposure, there is no inter-frame delay during which the sample can move, and motion artifacts that plague phase-stepped approaches are eliminated by design rather than corrected after the fact.

Photodamage is a second front on which the single-shot approach promises advantages. Phototoxicity in live-cell fluorescence microscopy scales with the total light dose delivered to the sample, and multi-frame super-resolution techniques necessarily illuminate the specimen repeatedly. By compressing the acquisition into a single exposure, SPIFFI reduces the number of illumination cycles required per reconstructed image, which can lower the cumulative dose and help keep living specimens healthy over longer observation windows. For experiments in which cells must be followed through division, differentiation, or stress responses over many minutes or hours, reducing light exposure is often as important as improving resolution, and imaging frameworks that economize on dose while preserving detail address a genuine unmet need.

Real-time capability also changes the experimental workflow in a more subtle way. When reconstruction requires lengthy offline computation, microscopists typically acquire data first and analyze it later, discovering only after the experiment ends whether the labeling was adequate, the focus was stable, or the biology behaved as expected. An imaging mode that produces super-resolved results in real time allows researchers to adjust conditions on the fly: to re-focus, re-label, or re-design the experiment while the sample is still on the stage. In the longer term, real-time super-resolution also makes live feedback experiments feasible, in which perturbations such as optogenetic activation or drug addition are triggered based on features detected in the super-resolved image itself, closing the loop between observation and intervention at a spatial scale previously reserved for slower, fixed-cell methods.

The technical challenges that SPIFFI had to overcome are nontrivial and illuminate why such a capability has been slow to arrive. Encoding polarization diversity into an optical system while preserving diffraction-limited image quality requires precise wavefront and polarization control, typically with patterned retarders, spatial light modulators, or polarization-sensitive optics arranged so that different polarization channels are spatially multiplexed onto the detector without crosstalk that would corrupt the reconstruction. The decoding algorithms must unmix these channels robustly in the presence of shot noise, background autofluorescence, and the inevitable imperfections of real optical components. Achieving this in a form that runs fast enough for real-time display demands efficient computational implementations, often leveraging modern graphics hardware. That SPIFFI achieves all of this while remaining usable on biological samples reflects years of incremental progress across polarization imaging, computational microscopy, and fluorescent probe chemistry.

For the broader microscopy community, SPIFFI represents part of a larger convergence between optical engineering and computational reconstruction that has come to define the current era of microscopy. The classical divide between what the optics measure and what the software infers has blurred: polarization, phase, spectrum, and incidence angle have all been conscripted as carriers of encoded spatial information, with algorithms doing the work of translation. Within this landscape, the appeal of single-shot designs is a growing recognition that biology cannot be asked to hold still. The techniques that ultimately shape our understanding of living systems will be those that deliver their full power within the timescales on which life unfolds, and by bringing super-resolution and multidimensional contrast into a single real-time exposure, SPIFFI marks a meaningful step in that direction. If the approach proves widely adoptable on standard microscopes, it could bring real-time, multidimensional super-resolution imaging out of specialized laboratories and into everyday use across cell biology, neuroscience, and biophysics.

Subject of Research: Single-shot polarimetric super-resolution fluorescence microscopy for live-cell imaging

Article Title: SPIFFI enables single-shot super-resolution and multidimensional imaging

Article References: Guo, W., Feletti, L., & Radenovic, A. (2026). SPIFFI enables single-shot super-resolution and multidimensional imaging. Nature Methods. https://doi.org/10.1038/s41592-026-03196-6

Image Credits: AI Generated

DOI: 10.1038/s41592-026-03196-6

Keywords: super-resolution microscopy, fluorescence imaging, polarimetry, live-cell imaging, structured illumination, single-shot imaging, real-time imaging, phototoxicity, computational microscopy, cell biology, SPIFFI, enables